XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible assets - Narrative (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dosing Of Specific Number Of Patients | Milestone Payment    
Disclosure of detailed information about intangible assets [line items]    
Additions $ 500  
Successful Completion Of In-Vivo Efficacy Studies | Milestone Payment    
Disclosure of detailed information about intangible assets [line items]    
Additions $ 195  
License To Acquire An Antibody, ZYNLONTA | Milestone Payment    
Disclosure of detailed information about intangible assets [line items]    
Additions   $ 1,050
ZYNLONTA    
Disclosure of detailed information about intangible assets [line items]    
Useful life measured as period of time, intangible assets other than goodwill   14 years
License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA | Milestone Payment    
Disclosure of detailed information about intangible assets [line items]    
Additions   $ 600
License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2) | License Payment    
Disclosure of detailed information about intangible assets [line items]    
Additions   $ 250